PortfoliosLab logo
Guardant Health, Inc. (GH)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US40131M1099

CUSIP

40131M109

IPO Date

Oct 4, 2018

Highlights

Market Cap

$4.78B

EPS (TTM)

-$3.42

Total Revenue (TTM)

$774.00M

Gross Profit (TTM)

$474.77M

EBITDA (TTM)

-$397.86M

Year Range

$20.14 - $52.92

Target Price

$59.55

Short %

7.73%

Short Ratio

3.50

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Guardant Health, Inc.

Popular comparisons:
GH vs. VOO GH vs. MRNA GH vs. EXAS
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Guardant Health, Inc. (GH) returned 32.96% year-to-date (YTD) and 47.87% over the past 12 months.


GH

YTD

32.96%

1M

-14.00%

6M

14.07%

1Y

47.87%

3Y*

-0.29%

5Y*

-14.78%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of GH, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202553.78%-9.43%0.12%10.87%-14.00%32.96%
2024-18.93%-13.36%8.58%-12.75%50.56%6.57%21.64%-27.18%-10.32%-4.62%62.75%-14.21%12.94%
202315.55%-1.72%-24.12%-3.75%29.96%22.10%8.99%0.15%-24.16%-12.69%-2.74%7.47%-0.55%
2022-30.46%-4.72%-0.05%-6.85%-33.58%-1.56%24.37%-0.22%7.53%-8.04%5.74%-48.03%-72.81%
202120.65%-5.35%3.72%4.15%-21.93%0.06%-11.59%15.91%-1.78%-6.58%-9.99%-4.85%-22.39%
2020-2.69%14.36%-19.96%10.57%17.45%-10.24%4.99%12.12%17.05%-4.58%13.56%6.41%64.93%
20197.32%65.20%15.10%-14.59%17.36%12.29%8.87%-6.87%-27.08%8.88%11.76%0.61%107.87%
20183.98%6.72%5.21%16.74%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 76, GH is among the top 24% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GH is 7676
Overall Rank
The Sharpe Ratio Rank of GH is 7676
Sharpe Ratio Rank
The Sortino Ratio Rank of GH is 8080
Sortino Ratio Rank
The Omega Ratio Rank of GH is 7373
Omega Ratio Rank
The Calmar Ratio Rank of GH is 7575
Calmar Ratio Rank
The Martin Ratio Rank of GH is 7676
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Guardant Health, Inc. (GH) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Guardant Health, Inc. Sharpe ratios as of May 31, 2025 (values are recalculated daily):

  • 1-Year: 0.73
  • 5-Year: -0.23
  • All Time: 0.05

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Guardant Health, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Guardant Health, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Guardant Health, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Guardant Health, Inc. was 91.03%, occurring on Apr 19, 2024. The portfolio has not yet recovered.

The current Guardant Health, Inc. drawdown is 77.32%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.03%Feb 16, 2021800Apr 19, 2024
-46.47%Aug 9, 2019151Mar 16, 2020135Sep 25, 2020286
-34.74%Mar 18, 201925Apr 22, 201975Aug 7, 2019100
-29.44%Dec 7, 201812Dec 24, 201835Feb 14, 201947
-19.99%Oct 18, 20188Oct 29, 201824Dec 3, 201832
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Guardant Health, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Guardant Health, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 42.4% positive surprise.


-1.40-1.20-1.00-0.80-0.60-0.40-0.2020212022202320242025
-0.49
-0.85
Actual
Estimate

Valuation

The Valuation section provides an overview of how Guardant Health, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for GH relative to other companies in the Diagnostics & Research industry. Currently, GH has a P/S ratio of 6.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for GH in comparison with other companies in the Diagnostics & Research industry. Currently, GH has a P/B value of 55.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items